Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q3 2022 vs. Q2 2022
How the institutions holding Aligos Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 60 | 52 | −8 |
| Shares | 29.8M | 27.6M | −2.16M (−7.2%) |
| Value | $36.0M | $30.4M | −$5.66M (−15.7%) |
New holders (5)
Institutions that held Aligos Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Rockefeller Capital Management L.P. | 77,499 | $85.0K | 0.00% |
| Bailard, Inc. | 19,400 | $21.0K | 0.00% |
| Balyasny Asset Management LLC | 11,999 | $13.0K | 0.00% |
| Federated Hermes, Inc. | 2,017 | $2.00K | 0.00% |
| China Universal Asset Management Co., Ltd. | 372 | $0 | 0.00% |
Sold out (13)
Institutions that held Aligos Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Boxer Capital, LLC | 1,526,048 | $1.85M |
| Charles Schwab Investment Management Inc | 73,986 | $90.0K |
| Silverarc Capital Management, LLC | 58,392 | $71.0K |
| AQR Capital Management LLC | 48,045 | $58.0K |
| Tri Locum Partners LP | 29,302 | $35.0K |
| Atom Investors LP | 22,685 | $27.0K |
| Wedmont Private Capital | 20,741 | $25.0K |
| Susquehanna International Group, LLP | 16,036 | $19.0K |
| ETF Managers Group, LLC | 13,489 | $17.0K |
| Hershey Trust Co | 4,552 | $6.00K |
| Barclays PLC | 2,933 | $4.00K |
| New York State Common Retirement Fund | 169 | $0 |
| Credit Suisse AG | 11 | $0 |